Tonny
Put AVXLD on your radar!
AVXLD have been stabilizing right about $9 dollars with a nice volume to boot!
Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.
ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.
A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.
ANAVEX PLUS is believed to be a compelling commercial opportunity. The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually. Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.
Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXLD
- Anavex to Present at 4th Annual OktoberINVESTfest ConferenceGlobeNewswire(Mon, Oct 12)
- ANAVEX LIFE SCIENCES CORP. FinancialsEDGAR Online Financials(Sat, Oct 10)
- Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 ConferenceGlobeNewswire(Wed, Oct 7)
- ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K/A, Material Modification to Rights of Security Holders, Change in DirecEDGAR Online(Wed, Oct 7)
- CORRECTING and REPLACING -- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock SplitGlobeNewswire(Tue, Oct 6)
- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock SplitGlobeNewswire(Tue, Oct 6)
- ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Material Modification to Rights of Security Holders, Change in DirectoEDGAR Online(Tue, Oct 6)
- Investors Exhibiting Increased Interest In Small Cap Stocks, Including CD International (CDII) And MoreAccesswire(Thu, Oct 1)
- ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, Sep 28)
- Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of ScheduleGlobeNewswire(Mon, Sep 28)
- Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference
I'll talk to you soon!
Stockpalooza.com Team
Never invest in a stock mentioned by StockPalooza.com.com unless you can afford to lose your entire investment.
Release of Liability: Through use of this website viewing or using you agree to holdStockPalooza.com.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please be advised that StockPalooza.com.com is often compensated for issuing press releases, profiles or opinions concerning particular companies, its opinion is therefore biased and you should consider the factor when evaluating StockPalooza.com.com's statements regarding a company. StockPalooza.com.com's officers and directors do not own any shares of the mentioned company(s). When StockPalooza.com.com receives free or restric ted trading shares as a compensation for a profiled company, StockPalooza.com .com may sell part or all of such shares during the period in which StockPalooza.com.com is performing such services. StockPalooza.com.com will disclose how many and what type of shares we have been compensated if we do receive shares or buy shares of a profiled company.StockPalooza.com.com expect to be compensated Two Hundred Thousand Dollars Cash via Bank Wire Transfer by a third party for a 1 Day Marketing Program regarding AVXLD. This compensation/expected compensation, expired or not, is a major conflict of interest in our ability to be unbiased. Therefore, this newsletter should be read as a commercial advertisement only. The third party, company, or their affiliates may wish to liquidate shares, which has the potential to hurt share prices . Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the t imeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. StockPalooza.com.comencourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockPalooza.com.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. StockPalooza.com.com, nor any of its affiliates are not registered investment. Stockpalooza's emails and alerts are intended for novelty purposes only.
11020 Vanowen St No. Hollywood CA 91605
|
|
|
|